COPY OF THE CLAIMS

1. (CURRENTLY AMENDED) A compound of the formula



1

or a pharmaceutically acceptable prodrug, salt or solvate thereof wherein:

~~each~~ R^1 and R^{10} ~~is~~ are each independently H or OH;

R^2 is H or C_1-C_6 alkyl wherein the foregoing R^2 alkyl group is optionally substituted by 1 or 2 R^4 groups;

~~each~~ R^3 is independently selected from C_6-C_{10} aryl or 5 to 10 membered heteroaromatic, and the heteroaromatic and aryl moieties of the foregoing R^3 groups are substituted by a –$CHR^9NR^{11}R^{12}$ group and optionally substituted by 1 to 4 R^4 groups;

~~each~~ R^4 is independently selected from, C_1-C_{10} alkyl, C_2-C_{10} alkenyl, C_2-C_{10} alkynyl, halo, cyano, nitro, trifluoromethyl, difluoromethyl, trifluoromethoxy, azido, hydroxy, C_1-C_6 alkoxy, $-C(O)R^5$, $-C(O)OR^5$, $-NR^6C(O)OR^8$, $-OC(O)R^5$, $-NR^6SO_2R^8$, $-SO_2NR^5R^6$, $-NR^6C(O)R^5$, $-C(O)NR^5R^6$, $-NR^5R^6$, $-S(O)_j(CR^6R^7)_m$(C_6-C_{10} aryl), $-S(O)_j$(C_1-C_6 alkyl), $-(CR^6R^7)_m$(C_6-C_{10} aryl), $-O(CR^6R^7)_m$(C_6-C_{10} aryl), $-NR^6(CR^6R^7)_m$(C_6-C_{10} aryl), $-(CR^6R^7)_m$(4 to 10 membered heterocyclic), $-C(O)(CR^6R^7)_m$(C_6-C_{10} aryl), and $-C(O)(CR^6R^7)_m$(4 to 10 membered heterocyclic), wherein m is an integer from 0 to 4; j is an integer from 0 to 2, and said alkyl, alkenyl, alkynyl, aryl and heterocyclic moieties of the foregoing R^4 groups are optionally substituted by 1 to 3 substituents independently selected from halo, cyano, nitro, trifluoromethyl, trifluoromethoxy, azido, $-NR^6SO_2R^8$, $-SO_2NR^5R^6$, $-C(O)R^5$, $-C(O)OR^5$, $-OC(O)R^5$, $-NR^6C(O)OR^8$, $-NR^6C(O)R^5$, $-C(O)NR^5R^6$, $-NR^5R^6$, $-OR^5$, C_1-C_{10} alkyl, $-(CR^6R^7)_m$(C_6-C_{10} aryl), and $-(CR^6R^7)_m$(4 to 10 membered heterocyclic), wherein m is an integer from 0 to 4;

each R^5, R^9, R^{11}, R^{12}, R^{13} and R^{14} is independently selected from H, C_1-C_{10} alkyl, -$(CR^6R^7)_m$(C_6-C_{10} aryl), -$(CR^6R^7)_m$(C_3-C_{10} cycloalkyl), indanyl and -$(CR^6R^7)_m$(4 to 10 membered heterocyclic), wherein m is an integer from 0 to 4, and the foregoing R^5 , R^{11}, R^9 and R^{12} substituents, except H, are optionally substituted by 1 to 3 substituents independently selected from halo, cyano, nitro, benzyl, trifluoromethyl, trifluoromethoxy, azido, -CH_2(C_2-C_6 alkenyl), -$C(O)R^6$, -$C(O)OR^6$, -$OC(O)R^6$, -$NR^6C(O)R^7$, -$C(O)NR^6R^7$, -NR^6R^7, hydroxy, C_1-C_6 alkyl, and C_1-C_6 alkoxy;

or R^{11} and R^{12} can be taken together to form a 4 to 7 membered heterocyclic group optionally substituted by one R^{14} group;

~~each~~ R^6 and R^7 ~~is~~ are each independently selected from H, -C(O)(C_1-C_6 alkyl), C_1-C_6 alkyl or -$(CH_2)_n$(C_6-C_{10} aryl) wherein n is an integer from 0 to 2, and the foregoing aryl substituents are optionally substituted by 1 to 3 substituents independently selected from halo, cyano, nitro, trifluoromethyl, trifluoromethoxy, and azido;

-NR^6R^7 can be taken together to form the following structure



; and

~~each~~ R^8 is selected from the substituents provided in the definition of R^5 except R^8 is not H.

2. (CURRENTLY AMENDED) A compound acccording to claim 1, ~~include those~~ wherein R^3 is phenyl substituted by one –$CH_2NR^{11}R^{12}$ group and optionally substituted by 1 to 4 R^4 groups; and the pharmaceutically acceptable salt, prodrug and solvate of said compound.

3. (CURRENTLY AMENDED) A compound according to claim 2 wherein said R^{11} and R^{12} groups are each independently selected from C_1-C_{10} alkyl, -$(CR^6R^7)_m$(C_6-C_{10} aryl), -$(CR^6R^7)_m$(C_3-C_{10} cycloalkyl), indanyl and -$(CR^6R^7)_m$(4 to 10 membered heterocyclic), wherein m is an integer from 0 to 4, and the foregoing, R^{11} and R^{12} substituents, are optionally substituted by 1 to 3 substituents independently selected from halo, benzyl, trifluoromethyl, trifluoromethoxy, -NR^6R^7; and the pharmaceutically acceptable salt, prodrug and solvate of said compound.

4. (CURRENTLY AMENDED) A compound according to claim 1 wherein one of the R^4 group is halo and ortho to the ether oxygen; and the pharmaceutically acceptable salt,

prodrug and solvate of said compound.

5. (CURRENTLY AMENDED) A compound according to claim 4 wherein said halo group is chlorine; and the pharmaceutically acceptable salt, prodrug and solvate of said compound.

6. (ORIGINAL) A compound according to claim 1 wherein said compound is selected from the group consisting of:

3-(4-{(2S,3S,4S,5R)-5-[3-{2-chloro-4-[(methyl-napthalen-1—ylmethyl-amino)-methyl]-phenoxy}-1-methyl-(1E)-propenyl]-3,4-dihydroxy-tetrahydro-furan-2-yloxy}-3-hydroxy-phenyl)-2-methyl-N-((3aS,4R,5R,6S,7R,7aR)-4,6,7-trihydroxy-hexahydro-benzo[1,3]dioxol-5-yl)-(2E)-acrylamide;

3-(4-{(2S,3S,4S,5R)-5-[3-(4-benzylaminomethyl-2-chloro-phenoxy)-1-methyl-(1E)-propenyl]-3,4-dihydroxy-tetrahydro-furan-2-yloxy}-3-hydroxy-phenyl)-2-methyl-N-((3aS,4R,5R,6S,7R,7aR)-4,6,7-trihydroxy-hexahydro-benzo[1,3]dioxol-5-yl)-(2E)-acrylamide;

3-(4-{(-{(2S,4S,5R)-5-[3-(4-{[Benzyl-(2-dimethylamino-ethyl)-amino]-methyl}-2-chloro-phenoxy)-1-methyl-(1E)-propenyl]-4-hydroxy-tetrahydro-furan-2-yloxy}-3-hydroxy-phenyl)-2-methyl-N-((3aS,4R,5R,6S,7R,7aR)-4,6,7-trihydroxy-hexahydro-benzo[1,3]dioxol-5-yl)-acrylamide

3-(4-{(2S,3S,4S,5R)-5-[3-(2,3-Dichloro-4-{[(3-dimethylamino-propyl)-ethyl-amino]-methyl}-phenoxy)-1-methyl-propenyl]-3,4-dihydroxy-tetrahydro-furan-2-yloxy}-3-hydroxy-phenyl)-2-methyl-N-((3aS,4R,5R,6S,7R,7aR)-4,6,7-trihydroxy-hexahydro-benzo[1,3]dioxol-5-yl)-acrylamide

3-(4-{(2S,3S,4S,5R)-5-[3-(4-(3-chloro-benzyl)aminomethyl-2-chloro-phenoxy)-1-methyl-(1Z)-propenyl]-3,4-dihydroxy-tetrahydro-furan-2-yloxy}-3-hydroxy-phenyl)-2-methyl-N-((3aS,4R,5R,6S,7R,7aR)-4,6,7-trihydroxy-hexahydro-benzo[1,3]dioxol-5-yl)-(2E)-acrylamide;

3-(4-{(2S,3S,4S,5R)-5-[3-(4-ethylamino-2-chloro-phenoxy)-1-methyl-(1E)-propenyl]-3,4-dihydroxy-tetrahydro-furan-2-yloxy}-3-hydroxy-phenyl)-2-methyl-N-((3aS,4R,5R,6S,7R,7aR)-4,6,7-trihydroxy-hexahydro-benzo[1,3]dioxol-5-yl)-(2E)-acrylamide;

3-(4-{(2S,3S,4S,5R)-5-[3-(3-piperidinyl-2-chloro-phenoxy)-1-methyl-(1E)-propenyl]-3,4-dihydroxy-tetrahydro-furan-2-yloxy}-3-hydroxy-phenyl)-2-methyl-N-

((3aS,4R,5R,6S,7R,7aR)-4,6,7-trihydroxy-hexahydro-benzo[1,3]dioxol-5-yl)-(2E)-acrylamide;

3-(4-{(2S,3S,4S,5R)-5-[3-(4-benzylaminomethyl-2-chloro-phenoxy)-1-methyl-(1E)-propenyl]-4-hydroxy-tetrahydro-furan-2-yloxy}-3-hydroxy-phenyl)-2-methyl-N-((3aS,4R,5R,6S,7R,7aR)-4,6,7-trihydroxy-hexahydro-benzo[1,3]dioxol-5-yl)-(2E)-acrylamide;

3-(4-{(2S,3S,4S,5R)-5-[3-{2-chloro-4-[(benzyl-methyl-amino)-methyl]-phenoxy}-1-methyl-(1E)-propenyl]-3,4-dihydroxy-tetrahydro-furan-2-yloxy}-3-hydroxy-phenyl)-2-methyl-N-((3aS,4R,5R,6S,7R,7aR)-4,6,7-trihydroxy-hexahydro-benzo[1,3]dioxol-5-yl)-(2E)-acrylamide;

3-(4-{(2S,3S,4S,5R)-5-[3-{2-chloro-4-[(ethyl-methyl-amino)-methyl]-phenoxy}-1-methyl-(1E)-propenyl]-3,4-dihydroxy-tetrahydro-furan-2-yloxy}-3-hydroxy-phenyl)-2-methyl-N-((3aS,4R,5R,6S,7R,7aR)-4,6,7-trihydroxy-hexahydro-benzo[1,3]dioxol-5-yl)-(2E)-acrylamide;

3-(4-{(2S,3S,4S,5R)-5-[3-{2-chloro-4-morpholin-4ylmethyl-phenoxy}-1-methyl-(1E)-propenyl]-3,4-dihydroxy-tetrahydro-furan-2-yloxy}-3-hydroxy-phenyl)-2-methyl-N-((3aS,4R,5R,6S,7R,7aR)-4,6,7-trihydroxy-hexahydro-benzo[1,3]dioxol-5-yl)-(2E)-acrylamide;

3-(4-{(2S,3S,4S,5R)-5-[3-(4-(3-chloro-benzyl)aminomethyl-2-chloro-phenoxy)-1-methyl-(1E)-propenyl]-3,4-dihydroxy-tetrahydro-furan-2-yloxy}-phenyl)-2-methyl-N-((3aS,4R,5R,6S,7R,7aR)-4,6,7-trihydroxy-hexahydro-benzo[1,3]dioxol-5-yl)-(2E)-acrylamide;

and the pharmaceutically acceptable salts, prodrugs and solvates of said compounds.

7. (CURRENTLY AMENDED) A pharmaceutical composition for the treatment of a bacterial infection, a protozoal infection, or a disorder related to a bacterial infection or a protozoal infection, in a mammal, fish, or bird which comprises a therapeutically effective amount of a compound, or a pharmaceutically acceptable prodrug, salt or solvate of said compound of claim 1 and a pharmaceutically acceptable carrier.

8. (CURRENTLY AMENDED) A method of treating a bacterial infection, a protozoal infection, or a disorder related to a bacterial infection or a protozoal infection, in a mammal, fish, or bird which comprises administering to said mammal, fish or bird a therapeutically effective amount of a compound, or a pharmaceutically acceptable prodrug, salt or solvate of said compound of claim 1.